Browsing Tag

Nasdaq:ADAP

Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies…

Jason Junior May 17, 2022

- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro - - Engineered TILs (ADP-TILIL7) intended…

Health

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

Jason Junior Sep 5, 2021

- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff - - Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET -…

Health

Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in…

Jason Junior May 20, 2021

- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - PHILADELPHIA and OXFORDSHIRE, United Kingdom,…